

COHEN, PONTANI, LIEBERMAN & PAVANE

COUNSELORS AT LAW
PATENTS, TRADEMARKS & COPYRIGHTS
651 FIFTH AVENUE
NEW YORK, NEW YORK 10176
TELEPHONE: 212-687-2770
FACSIMILE: 212-972-5487

FACSIMILE TRANSMISSION

From: Kent H. Cheng
Pages: 13 (including this page)

Date: 10/15/02 5:04 PM
Our File: 4830-15RCE

Please deliver to:

Examiner B. Badio	USPTO - Group 1616	1-703-746-5003
-------------------	--------------------	----------------

☐ Confirmation Will Follow

☐ Confirmation Will Not Follow

Notes/Comments:

This transmission may contain information which is privileged, constitutes attorney work product, or is otherwise protected from disclosure. Its contents are confidential and intended for the addressee only, and must not be used, copied, or disseminated by any person other than the addressee. The recipient is requested to notify the sender immediately of any error in transmission and to destroy any transmission not intended for the recipient. If you do not receive all pages or otherwise experience transmission difficulties, please call us at (212) 687-2770.

Received from < > at 10/15/02 5:04:10 PM [Eastern Daylight Time]

Attorney Docket # 4830-15RCE

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Perry Calias et al.

Serial No.: 09/543,489

Filed: April 06, 2000

For: Immunomodulatory Compositions and Methods
of Use Thereof

Examiner: B. Badio

Group Art: 1616

I hereby certify that this correspondence is being
replied to Examiner B. Badio at Group 1616 to
facsimile No. 1-703-746-5003 in the U.S. Patent and
Trademark Office, on

October 15, 2002

(Date of Deposit)

Kent H. Cheng

Name of applicant, assignee or Registered Representative

Kent H. Cheng

Signature

October 15, 2002

Date of Signature

Assistant Commissioner for Patents
Washington, DC 20231AMENDMENT

SIR:

In response to the Office Action dated July 12, 2002, please amend the above-identified
application as follows:

IN THE SPECIFICATION:

ye Please replace pages 14 through 16 with the attached replacement pages.

IN THE CLAIMS:

Please cancel claim 73.

Please amend claims 1, 2, 72 and 74 as follows:

- C' 1. (Amended) A pharmaceutical composition, comprising: